New hope for metastatic prostate cancer? early trial of GLR2037 begins

NCT ID NCT07468396

Not yet recruiting Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called GLR2037 in 65 men with metastatic prostate cancer that has spread to bones or soft tissues. The main goals are to check the drug's safety and how the body processes it. Participants will take GLR2037 daily in 28-day cycles. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLR2037 (an experimental drug taken daily in 28-day cycles)
What this could lead to: If successful, this could point toward a new treatment option for metastatic prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 65 participants, focused mainly on safety and dosing. The drug may not prove effective or could have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

No.8 Nanfeng West 1st Street, Huoxian, Tongzhou District

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.